Related Experiment Video
Updated: Jun 28, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Pazopanib stimulates senescence of renal carcinoma cells through targeting nuclear factor E2-related factor 2 (Nrf2)
Xingyuan Wang1, Jing Yang1, Dechao Li1
1Department of Urology, Harbin Medical University Cancer Hospital, Harbin, China.
Abstract:
Renal cell carcinoma (RCC) is the most common kidney cancer with high mortality rate. Pazopanib has been approved for the treatment of RCC. However, the underlying mechanism is not clear. Here, we report a novel finding by showing that treatment with Pazopanib could promote cellular senescence of the human RCC cell line ACHN. Cells were stimulated with 5, 10, and 20 μM Pazopanib, respectively. Cellular senescence was measured using senescence-associated β-galactosidase (SA-β-Gal) staining. Western blot analysis and real-time polymerase chain reaction were used to measure the mRNA and protein expression of nuclear factor E2-related factor 2 (Nrf2), γH2AX, human telomerase reverse transcriptase (hTERT), telomeric repeat binding factor 2 (TERF2), p53 and plasminogen activator inhibitor (PAI). First, we found that exposure to Pazopanib reduced the cell viability of ACHN cells. Additionally, Pazopanib induced oxidative stress by increasing the production of reactive oxygen species, reducing the levels of glutathione peroxidase, and promoting nuclear translocation of Nrf2. Interestingly, Pazopanib exposure resulted in DNA damage by increasing the expression of γH2AX. Importantly, Pazopanib increased cellular senescence and reduced telomerase activity. Pazopanib also reduced the gene expression of hTERT but increased the gene expression of TERF2. Correspondingly, we found that Pazopanib increased the expression of p53 and PAI at both the mRNA and protein levels. To elucidate the underlying mechanism, the expression of Nrf2 was knocked down by transduction with Ad- Nrf2 shRNA. Results indicate that silencing of Nrf2 in ACHN cells abolished the effects of Pazopanib in stimulating cellular senescence and reducing telomerase activity. Consistently, knockdown of Nrf2 restored the expression of p53 and PAI in ACHN cells. Based on these results, we explored a novel mechanism whereby which Pazopanib displays a cytotoxicity effect in RCC cells through promoting cellular senescence mediated by Nrf2.
Insights
Pazopanib, used for renal cell carcinoma (RCC), promotes cancer cell senescence and reduces telomerase activity by activating nuclear factor E2-related factor 2 (Nrf2). Silencing Nrf2 blocks these effects, revealing a novel mechanism of Pazopanib
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Renal cell carcinoma (RCC) presents a significant clinical challenge due to its high mortality rate.
- Pazopanib is an approved treatment for RCC, but its precise mechanism of action remains incompletely understood.
- Investigating novel therapeutic mechanisms is crucial for improving RCC patient outcomes.
Purpose of the Study:
- To elucidate the underlying mechanism of Pazopanib's cytotoxicity in human RCC cell line ACHN.
- To investigate the role of cellular senescence and nuclear factor E2-related factor 2 (Nrf2) in Pazopanib's anti-cancer effects.
Main Methods:
- Human RCC ACHN cells were treated with varying concentrations of Pazopanib.
- Cellular senescence was assessed via senescence-associated β-galactosidase (SA-β-Gal) staining.
- Key proteins and gene expression (Nrf2, γH2AX, hTERT, TERF2, p53, PAI) were analyzed using Western blot and real-time PCR.
- Nrf2 knockdown was performed to determine its role in Pazopanib's effects.
Main Results:
- Pazopanib reduced ACHN cell viability, induced oxidative stress, and caused DNA damage (increased γH2AX).
- Pazopanib treatment significantly increased cellular senescence and decreased telomerase activity.
- Nrf2 activation was critical, as Nrf2 knockdown abolished Pazopanib-induced senescence and telomerase inhibition.
- Pazopanib modulated the expression of p53 and plasminogen activator inhibitor (PAI) in an Nrf2-dependent manner.
Conclusions:
- Pazopanib exerts cytotoxicity in RCC cells by promoting Nrf2-mediated cellular senescence.
- This study reveals a novel mechanism involving Nrf2 in Pazopanib's anti-cancer activity.
- Targeting the Nrf2 pathway could offer new therapeutic strategies for RCC treatment.
More Related Videos
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
Replicative Cell Senescence
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

